12 January 2026 - AbbVie today announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans while protecting and investing in US pharmaceutical innovation.

The company will provide low prices in Medicaid while pledging $100 billion in US based research and development and capital investments, including manufacturing, over the next decade. AbbVie will also expand direct to patient offerings through TrumpRx for medicines used by millions of Americans, including Alphagan, Combigan, Humira and Synthroid.

Read AbbVie press release